Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Apple's new MacBooks delight critics, investors should care too, Barron's says » 10:03
11/28/20
11/28
10:03
11/28/20
10:03
AAPL

Apple

$116.45 /

+0.42 (+0.36%)

, INTC

Intel

$47.56 /

+0.5 (+1.06%)

Critics have been raving…

Critics have been raving about Apple's (AAPL) MacBook Air, MacBook Pro and Mac mini, which are all powered by Apple's new M1 chip, Alex Eule writes in this week's edition of Barron's. The reviews featured benchmarking scores that showed the base-level MacBook outperforming some of the most expensive Macs, which still use chips from Intel (INTC), the author adds. Apple consumers are happy again and investors shouldn't tune out Mac developments, Eule contends. Reference Link

ShowHide Related Items >><<
INTC Intel
$47.56 /

+0.5 (+1.06%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

11/25/20 Rosenblatt
Apple taking RF front-end in-house 'highly unlikely,' says Rosenblatt
11/25/20
Survey shows Apple demand outlook better than expected, says TF International
11/24/20 Credit Suisse
Apple iPhone 12 mini quickly reaches supply/demand balance, says Credit Suisse
11/23/20 Credit Suisse
iPhone 12 Pro/Pro Max extend, mini approaches equilibrium, says Credit Suisse
INTC Intel
$47.56 /

+0.5 (+1.06%)

11/23/20 Mizuho
Micron price target raised to $70 from $56 at Mizuho
11/13/20 Morgan Stanley
Few weeks delay of Ice Lake shouldn't be major Intel issue, says Morgan Stanley
11/13/20 Mizuho
Intel checks show Ice Lake delay not as bad as feared, says Mizuho
11/11/20 Credit Suisse
Credit Suisse likes move to Apple silicon on Mac, unified product portfolio
INTC Intel
$47.56 /

+0.5 (+1.06%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

INTC Intel
$47.56 /

+0.5 (+1.06%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

INTC Intel
$47.56 /

+0.5 (+1.06%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

INTC Intel
$47.56 /

+0.5 (+1.06%)

AAPL Apple
$116.45 /

+0.42 (+0.36%)

Friday
Hot Stocks
Cassava says USAN modifies drug candidate's chemical name to simufilam » 08:32
11/27/20
11/27
08:32
11/27/20
08:32
SAVA

Cassava Sciences

$7.70 /

+0.42 (+5.77%)

Cassava Sciences…

Cassava Sciences announced that the World Health Organization advised the United States Adopted Names Council to modify the chemical name of the Company's lead drug candidate to 'simufilam.' This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO's advice. Future references to Cassava Sciences' lead drug candidate for Alzheimer's disease will be simufilam.

ShowHide Related Items >><<
SAVA Cassava Sciences
$7.70 /

+0.42 (+5.77%)

SAVA Cassava Sciences
$7.70 /

+0.42 (+5.77%)

10/22/20 Cantor Fitzgerald
Cassava Sciences initiated with an Overweight at Cantor Fitzgerald
09/23/20 H.C. Wainwright
Cassava Sciences upgraded to Buy from Neutral at H.C. Wainwright
09/14/20 Maxim
Cassava upgraded to Buy at Maxim after second analysis of AD drug data
09/14/20 Maxim
Cassava Sciences upgraded to Buy from Hold at Maxim
SAVA Cassava Sciences
$7.70 /

+0.42 (+5.77%)

  • 13
    Nov
SAVA Cassava Sciences
$7.70 /

+0.42 (+5.77%)

SAVA Cassava Sciences
$7.70 /

+0.42 (+5.77%)

Wednesday
Hot Stocks
FDA says approval of remdesivir met 'legal and scientific standard' » 13:27
11/25/20
11/25
13:27
11/25/20
13:27
GILD

Gilead

$59.62 /

-0.63 (-1.05%)

The Food and Drug…

The Food and Drug Administration said the approval of Gilead's remdesivir, known as Veklury, for the treatment of patients hospitalized with COVID-19 met the "legal and scientific standard." FDA's approval of remdesivir was supported by the agency's "independent, in-depth analysis of data from three randomized, controlled clinical trials that included patients hospitalized with mild-to-severe COVID-19," the agency said in a statement. It added, "FDA is aware of the preprint describing the results of the SOLIDARITY trial, a World Health Organization-sponsored, open-label, randomized trial comparing different investigational interventions plus standard-of-care to standard-of-care alone in hospitalized patients with COVID-19. One of the drugs studied in SOLIDARITY was Veklury. The SOLIDARITY trial's primary goal was to assess for effects of treatment interventions on in-hospital mortality. Like the ACTT-1 trial discussed above, the SOLIDARITY trial did not find a statistically significant difference in mortality between the Veklury arm and the standard-of-care arm." Reference Link

ShowHide Related Items >><<
GILD Gilead
$59.62 /

-0.63 (-1.05%)

GILD Gilead
$59.62 /

-0.63 (-1.05%)

11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Berenberg
Arcus Biosciences initiated with a Buy at Berenberg
11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
GILD Gilead
$59.62 /

-0.63 (-1.05%)

GILD Gilead
$59.62 /

-0.63 (-1.05%)

GILD Gilead
$59.62 /

-0.63 (-1.05%)

GILD Gilead
$59.62 /

-0.63 (-1.05%)

Tuesday
Hot Stocks
Tiger Global led $131M in Series C funding for U.S. 'challenger bank' Current » 17:51
11/24/20
11/24
17:51
11/24/20
17:51
GS

Goldman Sachs

$237.86 /

+9.03 (+3.95%)

, PYPL

PayPal

$206.00 /

+5.08 (+2.53%)

, SQ

Square

$202.90 /

-4.89 (-2.35%)

, ALLY

Ally Financial

$31.07 /

+1.215 (+4.07%)

, COF

Capital One

$91.36 /

+4.07 (+4.66%)

, DFS

Discover

$81.56 /

+3.35 (+4.28%)

Mobile banking app…

Mobile banking app Current, which describes itself as a "challenger bank," announced on its website has raised $131M in Series C funding. Current continued, "New investor Tiger Global Management led the round for the mobile bank, which has now raised over $180M in total funding and has a valuation of $750M. The new capital follows a year of exponential growth for Current, which has doubled its member base in less than six months to surpass two million members. Revenue has also increased over 500 percent year over year to firmly establish the challenger bank as an industry leader in the U.S. We have seen a demonstrated need for access to affordable banking with a best-in-class mobile solution that Current is uniquely suited to provide," said Stuart Sopp, CEO and Founder, Current. "We are committed to building products specifically to improve the financial outcomes of the millions of hard-working Americans who live paycheck to paycheck, and whose needs are not being properly served by traditional banks. With this new round of funding we will continue to expand on our mission, growth and innovation to find more ways to get members their money faster, help them spend it smarter and help close the financial inequality gap." Publicly traded companies in the space include Goldman Sachs (GS), with its Marcus unit, PayPal's (PYPL) Venmo, bankers like Ally Financial (ALLY), Capital One (COF), Discover (DFS) and Square (SQ). Reference Link

ShowHide Related Items >><<
SQ Square
$202.90 /

-4.89 (-2.35%)

PYPL PayPal
$206.00 /

+5.08 (+2.53%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

DFS Discover
$81.56 /

+3.35 (+4.28%)

COF Capital One
$91.36 /

+4.07 (+4.66%)

ALLY Ally Financial
$31.07 /

+1.215 (+4.07%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

10/19/20 Credit Suisse
Goldman Sachs price target raised to $262 from $255 at Credit Suisse
10/15/20 BMO Capital
Goldman Sachs price target raised to $274 from $267 at BMO Capital
10/15/20 Oppenheimer
Goldman Sachs price target raised to $356 from $326 at Oppenheimer
10/15/20 Barclays
Goldman Sachs price target raised to $270 from $253 at Barclays
PYPL PayPal
$206.00 /

+5.08 (+2.53%)

11/19/20 Morgan Stanley
Growth of Square's Cash App may be impacted by needed fixes, says Morgan Stanley
11/19/20 Keefe Bruyette
Too early to know if new Google Pay is PayPal, Square threat, says KBW
11/10/20 Mizuho
PayPal price target lowered to $270 from $290 at Mizuho
11/05/20 DZ Bank
PayPal upgraded to Buy from Hold at DZ Bank
SQ Square
$202.90 /

-4.89 (-2.35%)

11/19/20 Mizuho
Square price target raised to $300 from $225 at Mizuho
11/16/20 KeyBanc
Square price target raised to $250 from $215 at KeyBanc
ALLY Ally Financial
$31.07 /

+1.215 (+4.07%)

10/19/20 BMO Capital
Ally Financial price target raised to $36 from $34 at BMO Capital
10/09/20 JPMorgan
Ally Financial price target raised to $30 from $23.50 at JPMorgan
09/23/20 Piper Sandler
Ally Financial price target raised to $31 from $27 at Piper Sandler
08/24/20 Stephens
Stephens would be long Ally Financial into CFO presentation at conference
COF Capital One
$91.36 /

+4.07 (+4.66%)

11/18/20 Compass Point
Capital One price target raised to $102 from $78 at Compass Point
11/12/20 Piper Sandler
Capital One price target raised to $105 from $93 at Piper Sandler
10/26/20 BMO Capital
Capital One price target raised to $133 from $127 at BMO Capital
10/26/20 Deutsche Bank
Capital One price target raised to $83 from $73 at Deutsche Bank
DFS Discover
$81.56 /

+3.35 (+4.28%)

11/17/20 Piper Sandler
Discover price target raised to $80 from $70 at Piper Sandler
10/23/20 BMO Capital
Discover price target raised to $80 from $76 at BMO Capital
10/23/20 RBC Capital
Discover price target raised to $75 from $61 at RBC Capital
10/23/20 Deutsche Bank
Discover price target raised to $74 from $55 at Deutsche Bank
SQ Square
$202.90 /

-4.89 (-2.35%)

PYPL PayPal
$206.00 /

+5.08 (+2.53%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

DFS Discover
$81.56 /

+3.35 (+4.28%)

COF Capital One
$91.36 /

+4.07 (+4.66%)

ALLY Ally Financial
$31.07 /

+1.215 (+4.07%)

SQ Square
$202.90 /

-4.89 (-2.35%)

PYPL PayPal
$206.00 /

+5.08 (+2.53%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

DFS Discover
$81.56 /

+3.35 (+4.28%)

COF Capital One
$91.36 /

+4.07 (+4.66%)

SQ Square
$202.90 /

-4.89 (-2.35%)

PYPL PayPal
$206.00 /

+5.08 (+2.53%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

DFS Discover
$81.56 /

+3.35 (+4.28%)

COF Capital One
$91.36 /

+4.07 (+4.66%)

ALLY Ally Financial
$31.07 /

+1.215 (+4.07%)

SQ Square
$202.90 /

-4.89 (-2.35%)

PYPL PayPal
$206.00 /

+5.08 (+2.53%)

GS Goldman Sachs
$237.86 /

+9.03 (+3.95%)

DFS Discover
$81.56 /

+3.35 (+4.28%)

COF Capital One
$91.36 /

+4.07 (+4.66%)

ALLY Ally Financial
$31.07 /

+1.215 (+4.07%)

Initiation
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI » 16:58
11/24/20
11/24
16:58
11/24/20
16:58
AVIR

Atea Pharmaceuticals

$34.00 /

+0.38 (+1.13%)

, GILD

Gilead

$60.25 /

+0.37 (+0.62%)

Evercore ISI analyst Umer…

Evercore ISI analyst Umer Raffat initiated coverage of Atea Pharmaceuticals (AVIR) with an Outperform rating. The analyst noted that oral antivirals for COVID-19 are still important, and that Atea is heading into a Phase 3 trial with an oral antiviral shortly. Raffat believes an antiviral Phase 3 trial for Atea could be better designed than how Gilead (GILD) ran it earlier in the pandemic.

ShowHide Related Items >><<
GILD Gilead
$60.25 /

+0.37 (+0.62%)

AVIR Atea Pharmaceuticals
$34.00 /

+0.38 (+1.13%)

AVIR Atea Pharmaceuticals
$34.00 /

+0.38 (+1.13%)

11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
11/24/20 JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
11/24/20 William Blair
William Blair starts Atea Pharmaceuticals with Outperform, $60 fair value
11/24/20 William Blair
Atea Pharmaceuticals initiated with an Outperform at William Blair
GILD Gilead
$60.25 /

+0.37 (+0.62%)

11/24/20 Berenberg
Arcus Biosciences initiated with a Buy at Berenberg
11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
GILD Gilead
$60.25 /

+0.37 (+0.62%)

  • 30
    Oct
GILD Gilead
$60.25 /

+0.37 (+0.62%)

GILD Gilead
$60.25 /

+0.37 (+0.62%)

AVIR Atea Pharmaceuticals
$34.00 /

+0.38 (+1.13%)

GILD Gilead
$60.25 /

+0.37 (+0.62%)

Initiation
Arcus Biosciences initiated with a Buy at Berenberg » 06:37
11/24/20
11/24
06:37
11/24/20
06:37
RCUS

Arcus Biosciences

$25.77 /

+1.365 (+5.59%)

, GILD

Gilead

$59.88 /

-0.22 (-0.37%)

Berenberg analyst…

Berenberg analyst Zhiqiang Shu initiated coverage of Arcus Biosciences (RCUS) with a Buy rating and $50 price target. Arcus' potential to develop therapies for multiple cancers is under-appreciated, contends Shu, who views the ten-year collaboration with Gilead (GILD) as "a vote of confidence" in Arcus.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$25.77 /

+1.365 (+5.59%)

GILD Gilead
$59.88 /

-0.22 (-0.37%)

RCUS Arcus Biosciences
$25.77 /

+1.365 (+5.59%)

11/23/20 Evercore ISI
Arcus Biosciences initiated with an Outperform at Evercore ISI
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
GILD Gilead
$59.88 /

-0.22 (-0.37%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
RCUS Arcus Biosciences
$25.77 /

+1.365 (+5.59%)

GILD Gilead
$59.88 /

-0.22 (-0.37%)

  • 29
    May
GILD Gilead
$59.88 /

-0.22 (-0.37%)

RCUS Arcus Biosciences
$25.77 /

+1.365 (+5.59%)

GILD Gilead
$59.88 /

-0.22 (-0.37%)

GILD Gilead
$59.88 /

-0.22 (-0.37%)

Periodicals
Intel quietly shuts down AR/VR project Intel Studios, Protocol reports » 06:12
11/24/20
11/24
06:12
11/24/20
06:12
INTC

Intel

$46.04 /

+0.64 (+1.41%)

Intel quietly shut down…

Intel quietly shut down Intel Studios, a 10,000-square-foot volumetric capture stage in Los Angeles, last month, Protocol's Janko Roettgers reports. Intel confirmed the closure in a statement sent to Protocol: "We're proud of the impact Intel Studios has made in the industry and its role in growing the immersive entertainment category. Although we are closing Intel Studios due to business conditions, we look forward to where the entertainment industry moves in the future." The AR/VR project was opened in early 2018. Reference Link

ShowHide Related Items >><<
INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

11/23/20 Mizuho
Micron price target raised to $70 from $56 at Mizuho
11/13/20 Morgan Stanley
Few weeks delay of Ice Lake shouldn't be major Intel issue, says Morgan Stanley
11/13/20 Mizuho
Intel checks show Ice Lake delay not as bad as feared, says Mizuho
11/11/20 Credit Suisse
Credit Suisse likes move to Apple silicon on Mac, unified product portfolio
INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

Monday
Hot Stocks
VeriSign reports Q3 domain name registrations 370.7M, up 0.2% from Q2, up 3% y/y » 16:30
11/23/20
11/23
16:30
11/23/20
16:30
VRSN

VeriSign

$196.47 /

+0.18 (+0.09%)

VeriSign announced that…

VeriSign announced that Q3 of 2020 closed with 370.7 million domain name registrations across all top-level domains, an increase of 0.6M domain name registrations, or 0.2%, compared to the second quarter of 2020. Domain name registrations have grown by 10.8M, or 3.0%, year over year. The .com and .net TLDs had a combined total of 163.7 million domain name registrations in the domain name base3 at the end of the third quarter of 2020, an increase of 1.7 million domain name registrations, or 1.0 percent, compared to the second quarter of 2020. The .com and .net TLDs had a combined increase of 6.3 million domain name registrations, or 4.0 percent, year over year. As of Sept. 30, 2020, the .com domain name base totaled 150.3 million domain name registrations, and the .net domain name base totaled 13.4 million domain name registrations. New .com and .net domain name registrations totaled 10.9 million at the end of the third quarter of 2020, compared to 9.9 million domain name registrations at the end of the third quarter of 2019.

ShowHide Related Items >><<
VRSN VeriSign
$196.47 /

+0.18 (+0.09%)

VRSN VeriSign
$196.47 /

+0.18 (+0.09%)

04/24/20 Baird
VeriSign price target raised to $250 from $220 at Baird
VRSN VeriSign
$196.47 /

+0.18 (+0.09%)

VRSN VeriSign
$196.47 /

+0.18 (+0.09%)

Options
Gilead put volume heavy and directionally bearish » 10:35
11/23/20
11/23
10:35
11/23/20
10:35
GILD

Gilead

$59.93 /

-0.17 (-0.28%)

Bearish flow noted in…

Bearish flow noted in Gilead with 11,604 puts trading, or 3x expected. Most active are 11/27 weekly 55 puts and 11/27 weekly 57 puts, with total volume in those strikes near 10,200 contracts. The Put/Call Ratio is 1.54, while ATM IV is up over 1 point on the day. Earnings are expected on February 2nd.

ShowHide Related Items >><<
GILD Gilead
$59.93 /

-0.17 (-0.28%)

GILD Gilead
$59.93 /

-0.17 (-0.28%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
GILD Gilead
$59.93 /

-0.17 (-0.28%)

GILD Gilead
$59.93 /

-0.17 (-0.28%)

GILD Gilead
$59.93 /

-0.17 (-0.28%)

GILD Gilead
$59.93 /

-0.17 (-0.28%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 10:25
11/23/20
11/23
10:25
11/23/20
10:25
GILD

Gilead

$59.85 /

-0.25 (-0.42%)

, LLY

Eli Lilly

$143.43 /

-2.21 (-1.52%)

, REGN

Regeneron

$521.45 /

+1.88 (+0.36%)

, HGEN

Humanigen

$8.72 /

-0.15 (-1.69%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.